Cancer Prevention-Interception Targeted Agent Discovery Program (CAP-IT)

The Cancer Prevention-Interception Targeted Agent Discovery Program (CAP-IT) is a collaborative research network with the overarching goal of discovering molecularly or immunologically targeted agents designed to prevent or intercept the oncogenic process in higher-risk populations. For the purpose of the funding opportunities that will support this discovery research initiative, cancer prevention is defined as primary prevention of cancer before the oncogenic process begins, while cancer interception refers to disruption of the oncogenic process during the precursor or precancer state or stage. The program focuses on advancing promising efficacious agents to the NCI’s existing R&D pipelines, PREVENT Cancer Preclinical Drug Development Program (PREVENT) and Cancer Prevention Clinical Trials Network (CP-CTNet) for further development, thereby establishing a concerted roadmap for streamlining the drug development process through the gamut of steps from discovery to early phase clinical trials.

Read more About Cancer Prevention-Interception Targeted Agent Discovery Program (CAP-IT)